Skip to main content


Figure 4 | BMC Pharmacology and Toxicology

Figure 4

From: Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes

Figure 4

Daily dose of anakinra (mg/kg, thick curve) as a function of bodyweight in order to reach the mean anakinra steady-state concentration of 0.4 mg/L. The 0.4 mg/L target corresponds to a maximal effect on the CRP biological marker of inflammation. Bold text in rectangles defines possible mean dosage recommendation for 3 bodyweight ranges. Text on top side stands for the maximal dosage in the corresponding bodyweight range.

Back to article page